Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia

R. A. Mesa, Ayalew Tefferi, T. S. Lasho, D. Loegering, R. F. McClure, H. L. Powell, N. T. Dai, D. P. Steensma, Scott H Kaufmann

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

An activating point mutation in Janus kinase 2 (JAK2 V617F) was recently identified in myelofibrosis with myeloid metaplasia (MMM). To further elucidate the pathogenic significance, we examined the JAK2 mutation burden, phosphorylation of JAK2 substrates and neutrophil apoptotic resistance. Immunoblotting revealed phosphorylation of signal transducer and activator of transcription-3 (STAT3) in all four JAK2 with high V617F mutant allele burden and seven of eight with intermediate mutant allele burden, but only one of eight with wild-type JAK2 (P<0.001). In contrast, STAT5 phosphorylation was undetectable in patient MMM neutrophils; and phosphorylation of Akt and extracellular signal-regulated kinases (ERKs) failed to correlate with JAK2 mutation status. Apoptosis was lower in MMM neutrophils (median 41% apoptotic cells, n=50) compared to controls (median 66%, n=9) or other myeloproliferative disorder patients (median 53%, n=11; P=0.002). Apoptotic resistance in MMM correlated with anemia (P=0.01) and the JAK2-V617F (P=0.01). Indeed, apoptotic resistance was greatest in MMM neutrophils with high mutant allele burden (median 22% apoptosis, n=5) than with intermediate burden (median 39%, n=23) or wild-type JAK2 (median 47%, n=22; P=0.008). These results suggest that mutant JAK2 contributes to MMM pathogenesis by constitutively phosphorylating STAT3 and diminishing myeloid cell apoptosis.

Original languageEnglish (US)
Pages (from-to)1800-1808
Number of pages9
JournalLeukemia
Volume20
Issue number10
DOIs
StatePublished - Oct 2006

Fingerprint

Janus Kinase 2
STAT3 Transcription Factor
Primary Myelofibrosis
Neutrophils
Phosphorylation
Apoptosis
Mutation
Alleles
Myeloproliferative Disorders
Extracellular Signal-Regulated MAP Kinases
Myeloid Cells
Point Mutation
Immunoblotting
Anemia

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia. / Mesa, R. A.; Tefferi, Ayalew; Lasho, T. S.; Loegering, D.; McClure, R. F.; Powell, H. L.; Dai, N. T.; Steensma, D. P.; Kaufmann, Scott H.

In: Leukemia, Vol. 20, No. 10, 10.2006, p. 1800-1808.

Research output: Contribution to journalArticle

Mesa, R. A. ; Tefferi, Ayalew ; Lasho, T. S. ; Loegering, D. ; McClure, R. F. ; Powell, H. L. ; Dai, N. T. ; Steensma, D. P. ; Kaufmann, Scott H. / Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia. In: Leukemia. 2006 ; Vol. 20, No. 10. pp. 1800-1808.
@article{96c6095a11c044e4b460bcf7755e5a54,
title = "Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia",
abstract = "An activating point mutation in Janus kinase 2 (JAK2 V617F) was recently identified in myelofibrosis with myeloid metaplasia (MMM). To further elucidate the pathogenic significance, we examined the JAK2 mutation burden, phosphorylation of JAK2 substrates and neutrophil apoptotic resistance. Immunoblotting revealed phosphorylation of signal transducer and activator of transcription-3 (STAT3) in all four JAK2 with high V617F mutant allele burden and seven of eight with intermediate mutant allele burden, but only one of eight with wild-type JAK2 (P<0.001). In contrast, STAT5 phosphorylation was undetectable in patient MMM neutrophils; and phosphorylation of Akt and extracellular signal-regulated kinases (ERKs) failed to correlate with JAK2 mutation status. Apoptosis was lower in MMM neutrophils (median 41{\%} apoptotic cells, n=50) compared to controls (median 66{\%}, n=9) or other myeloproliferative disorder patients (median 53{\%}, n=11; P=0.002). Apoptotic resistance in MMM correlated with anemia (P=0.01) and the JAK2-V617F (P=0.01). Indeed, apoptotic resistance was greatest in MMM neutrophils with high mutant allele burden (median 22{\%} apoptosis, n=5) than with intermediate burden (median 39{\%}, n=23) or wild-type JAK2 (median 47{\%}, n=22; P=0.008). These results suggest that mutant JAK2 contributes to MMM pathogenesis by constitutively phosphorylating STAT3 and diminishing myeloid cell apoptosis.",
author = "Mesa, {R. A.} and Ayalew Tefferi and Lasho, {T. S.} and D. Loegering and McClure, {R. F.} and Powell, {H. L.} and Dai, {N. T.} and Steensma, {D. P.} and Kaufmann, {Scott H}",
year = "2006",
month = "10",
doi = "10.1038/sj.leu.2404338",
language = "English (US)",
volume = "20",
pages = "1800--1808",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia

AU - Mesa, R. A.

AU - Tefferi, Ayalew

AU - Lasho, T. S.

AU - Loegering, D.

AU - McClure, R. F.

AU - Powell, H. L.

AU - Dai, N. T.

AU - Steensma, D. P.

AU - Kaufmann, Scott H

PY - 2006/10

Y1 - 2006/10

N2 - An activating point mutation in Janus kinase 2 (JAK2 V617F) was recently identified in myelofibrosis with myeloid metaplasia (MMM). To further elucidate the pathogenic significance, we examined the JAK2 mutation burden, phosphorylation of JAK2 substrates and neutrophil apoptotic resistance. Immunoblotting revealed phosphorylation of signal transducer and activator of transcription-3 (STAT3) in all four JAK2 with high V617F mutant allele burden and seven of eight with intermediate mutant allele burden, but only one of eight with wild-type JAK2 (P<0.001). In contrast, STAT5 phosphorylation was undetectable in patient MMM neutrophils; and phosphorylation of Akt and extracellular signal-regulated kinases (ERKs) failed to correlate with JAK2 mutation status. Apoptosis was lower in MMM neutrophils (median 41% apoptotic cells, n=50) compared to controls (median 66%, n=9) or other myeloproliferative disorder patients (median 53%, n=11; P=0.002). Apoptotic resistance in MMM correlated with anemia (P=0.01) and the JAK2-V617F (P=0.01). Indeed, apoptotic resistance was greatest in MMM neutrophils with high mutant allele burden (median 22% apoptosis, n=5) than with intermediate burden (median 39%, n=23) or wild-type JAK2 (median 47%, n=22; P=0.008). These results suggest that mutant JAK2 contributes to MMM pathogenesis by constitutively phosphorylating STAT3 and diminishing myeloid cell apoptosis.

AB - An activating point mutation in Janus kinase 2 (JAK2 V617F) was recently identified in myelofibrosis with myeloid metaplasia (MMM). To further elucidate the pathogenic significance, we examined the JAK2 mutation burden, phosphorylation of JAK2 substrates and neutrophil apoptotic resistance. Immunoblotting revealed phosphorylation of signal transducer and activator of transcription-3 (STAT3) in all four JAK2 with high V617F mutant allele burden and seven of eight with intermediate mutant allele burden, but only one of eight with wild-type JAK2 (P<0.001). In contrast, STAT5 phosphorylation was undetectable in patient MMM neutrophils; and phosphorylation of Akt and extracellular signal-regulated kinases (ERKs) failed to correlate with JAK2 mutation status. Apoptosis was lower in MMM neutrophils (median 41% apoptotic cells, n=50) compared to controls (median 66%, n=9) or other myeloproliferative disorder patients (median 53%, n=11; P=0.002). Apoptotic resistance in MMM correlated with anemia (P=0.01) and the JAK2-V617F (P=0.01). Indeed, apoptotic resistance was greatest in MMM neutrophils with high mutant allele burden (median 22% apoptosis, n=5) than with intermediate burden (median 39%, n=23) or wild-type JAK2 (median 47%, n=22; P=0.008). These results suggest that mutant JAK2 contributes to MMM pathogenesis by constitutively phosphorylating STAT3 and diminishing myeloid cell apoptosis.

UR - http://www.scopus.com/inward/record.url?scp=33750077275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750077275&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2404338

DO - 10.1038/sj.leu.2404338

M3 - Article

C2 - 16871275

AN - SCOPUS:33750077275

VL - 20

SP - 1800

EP - 1808

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 10

ER -